VivoSeq
Other

Longevity

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Longevity is an early-stage landscape with 0 programs across 1 company. The most active players are Sam Treadway.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

40/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Sam Treadway

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

5

clinical trials

Completed2 · 40%
Terminated2 · 40%
Active, not recruiting1 · 20%

Clinical Trials

Trial Activity

The Effect of Prophylactic FFP Administration on ECMO Circuit Longevity
Completed·—·N/A·NCT01903863·31 enrolled
Study of Acarbose in Longevity
Terminated·MMontefiore Medical Center·Phase 2·NCT02953093·28 enrolled
Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study
Completed·AAgelessRx·Phase 2·NCT04488601·129 enrolled
Ppar-Gamma EliminAtes Restenosis Longevity Study: PEARLS
Terminated·MMedstar Health Research Institute·Phase 3·NCT00465296·200 enrolled
An Open Label Study to Assess the Effect of a Food Supplement on Markers of Cellular Ageing and Longevity
Active, not recruiting·—·Preclinical·NCT07659834·18 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)